Pharma BD Deal Intelligence
Clinical vindication, business abandonment: Sangamo's SB-525 gene therapy delivered a winning Phase 3 AFFINE readout (1.24 vs 4.73 annualized bleeding rate) seven years after Pfizer's $70M-upfront, $545M-potential deal—yet Pfizer terminated the collaboration anyway.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer expanded its hemophilia gene therapy pipeline through the SB-525 collaboration with Sangamo, viewed as a major validation of Sangamo's AAV platform and…
104-week Alta Phase 1/2 data showed sustained Factor VIII expression and reduced annualized bleeding rates at the highest dose, positioning giroctocogene…
Phase 3 AFFINE study met primary endpoint of non-inferiority and superiority on total annualized bleeding rate (1.24 vs 4.73 with FVIII prophylaxis,…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Sangamo and Pfizer entered an exclusive global collaboration for SB-525 hemophilia A gene therapy and additional cDNA AAV programs. Sangamo received $70M upfront plus eligibility for up to $475M in milestones ($300M for SB-525 development/commercialization) plus tiered double-digit royalties. Pfizer assumed responsibility for global pivotal development, manufacturing and commercialization following Phase 1/2.
Hemophilia A is an X-linked genetic bleeding disorder caused by deficient or defective Factor VIII clotting protein. It affects almost exclusively males, who experience spontaneous and trauma-related bleeding into joints and soft tissue that, untreated, leads to chronic arthropathy and disability. The standard of care is lifelong prophylactic Factor VIII replacement infusions, a treatment burden that gene therapy aims to reduce or eliminate with a single dose.
At deal signing in 2017, the hemophilia A market was dominated by recombinant Factor VIII replacement (Shire/Takeda's Advate and Adynovate, Bayer's Kogenate/Kovaltry, Novo Nordisk's NovoEight, Bioverativ's Eloctate extended half-life) plus Roche/Genentech's then-newly approved Hemlibra (emicizumab), a bispecific subcutaneous prophylactic that quickly disrupted the standard of care. Gene therapy emerged as the next frontier: BioMarin's valoctocogene roxaparvovec (Roctavian) was the leading AAV5 program; Spark/Pfizer's SPK-8011 (fidanacogene elaparvovec was the hem B asset) and Sangamo/Pfizer's SB-525 (giroctocogene fitelparvovec, AAV6) were the principal AAV-FVIII competitors. The Pfizer-Sangamo deal positioned a Big Pharma to commercialize a one-time AAV6 FVIII therapy with potentially favorable durability versus AAV5 candidates. Pfizer's 2022 Phase 1/2 Alta data and 2024 AFFINE Phase 3 readout (ABR 1.24 vs 4.73 prophylaxis, p=0.004) validated the platform, though Pfizer subsequently elected not to commercialize and returned rights to Sangamo in 2024-2025, reshaping the competitive map.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Sangamo Therapeutics, Inc. (this deal) | 2017 | $545M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2017 deals · Pfizer Inc. deals · Hematology deals